Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial.
about
Venlafaxine for neuropathic pain in adultsNeuropathic cancer pain: What we are dealing with? How to manage it?Chemotherapy-induced peripheral neurotoxicity: a critical analysisVincristine-induced peripheral neuropathy in pediatric cancer patientsSymptom management in the older adult: 2015 updateGemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib.Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients.Pain in cancer survivorsA phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivorsNorth Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled studyTherapeutic strategies for cancer treatment related peripheral neuropathies.Phase I clinical trial of ifosfamide, oxaliplatin, and etoposide (IOE) in pediatric patients with refractory solid tumorsAssociation between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy: a systematic review and meta-analysis.Pilot evaluation of Scrambler therapy for the treatment of chemotherapy-induced peripheral neuropathyPlatinum-induced neurotoxicity and preventive strategies: past, present, and futureMC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy.Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy.Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients.Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance).Serotonin-norepinephrine reuptake inhibitors for the management of chemotherapy-induced peripheral neuropathy.Management options for established chemotherapy-induced peripheral neuropathy.Occupational exposure to municipal solid wastes and development of toxic neuropathies: possible role of nutrient supplementation, complementary and alternative medicines in chemoprevention.Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review.Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain.Psychopharmacology in cancer.Minimizing chemotherapy-induced peripheral neuropathy: preclinical and clinical development of new perspectives.Pregabalin in Chemotherapy Induced Neuropathic Pain.Pregabalin for the Prevention of Oxaliplatin-Induced Painful Neuropathy: A Randomized, Double-Blind Trial.Chemotherapy-induced peripheral neuropathy: limitations in current prophylactic strategies and directions for future research.Serotonin-norepinephrine reuptake inhibitors and the influence of binding affinity (Ki) on analgesia.Pharmacological Treatment of Pain in Cancer Patients: The Role of Adjuvant Analgesics, a Systematic Review.Use of an alpha lipoic, methylsulfonylmethane and bromelain dietary supplement (Opera®) for chemotherapy-induced peripheral neuropathy management, a prospective study.Vitamin E does not decrease the incidence of chemotherapy-induced peripheral neuropathy: a meta-analysis.Efficacy of venlafaxine for the relief of taxane and oxaliplatin-induced acute neurotoxicity: a single-center retrospective case-control study.Pain in chemotherapy-induced peripheral neurotoxicity.Oxaliplatin-induced neuropathy in colorectal cancerThe effect of curcumin on oxaliplatin and cisplatin neurotoxicity in rats: some behavioral, biochemical, and histopathological studiesPreventive effect of central administration of venlafaxine on morphine physical dependence, nociception, and blood cortisol level in rat.Venlafaxine Attenuates Heat Hyperalgesia Independent of Adenosine or Opioid System in a Rat Model of Peripheral NeuropathyIdentification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV.
P2860
Q24187793-DA20DB09-99BF-4FB2-89F2-DC0AFB5DB354Q26998945-518A8B40-757E-49DD-8E99-B6DE2FB83BA9Q27010318-899C7779-6D76-42FD-A360-3EF1B6A11C03Q28078232-C248011B-8866-400D-87CE-BF40A28BAA17Q30374202-0415A41F-C617-43A4-94AD-9E953FCB86F6Q33400294-AEC4716B-CC00-4AC2-91D8-25A5951129B4Q33561260-E278568A-1A9C-4C32-A51C-C77087C59D8EQ33650576-DD4D8A64-461A-4E89-B003-3BC594BF7CCCQ33693343-0AD49209-6036-4691-84C2-17C5C076322EQ33717608-FA708230-42B1-460A-8652-E3A3228435D1Q34433406-97A8DDCB-987C-4947-9C25-F71375725FDDQ34725699-207D265E-1EFB-4879-848F-73DEAD346536Q34733071-42F11E0C-C5F0-4981-86C7-ACAC3165378DQ35248891-D695DA95-9B93-4BB6-8D53-61FEE55FB86FQ35345734-BA58FC6F-B565-4E6D-8EB2-1D818CFF836DQ37082272-6CB7EBCD-2001-467B-82B8-398C0A3B15EAQ37325728-58C262DE-87C4-4743-9B9C-C899F6B94764Q37408810-ADBDCF1D-A1C3-42C4-B24A-F5FF8D8A5CA3Q37662241-6A581E5B-3627-41AF-896F-35C36069F770Q38191773-DA9EE387-5ACD-4B5B-A8BB-3E3922DE5E0BQ38216217-8733ED32-E864-441A-B273-8ABF4CC9EC10Q38217325-D4FDD49C-D30B-4921-963E-7D8F6C2F5E34Q38254351-4065600E-2429-4EBD-888E-E8F4E4A862FCQ38264622-53293B8D-87EE-4DD2-8F67-C8E9627A97AFQ38270608-04D5F323-7079-4060-9920-32C7F1597FE8Q38522262-0DE089DE-CD72-4B39-9215-3C4C40DD980CQ38644156-8E7B2466-13B2-47F0-93FA-1C0D931C61B8Q38708085-7900AF67-5DE3-4520-92FF-49FB9D0C9EB7Q38769139-E0817CC3-5724-4335-BD53-A81E4A32061CQ38786561-57FEF01D-2B07-4DA2-B5CA-189513B3AC5FQ38840224-BEC4E995-BB52-45ED-BF87-41FEADF1AC36Q38958436-168AD5EF-8658-422A-919D-5AA2EDDD4B96Q38959385-6BE8B87A-5237-4F9F-BEBA-76A7A30C6AA8Q39181038-B5BC5ACF-8AAE-4B9F-BF58-4C284506FB50Q39363713-C84F8323-1250-49EB-A9DC-E93F0B802FF6Q39803653-9A003802-19DA-4E60-82D6-802F03B40D8FQ42000475-4096AC02-EB96-410E-B338-1A6787A06448Q42133806-66F01D38-798D-4605-B289-4250B685B239Q42150016-427E41D5-391B-4207-84F3-81E50B6CF9E7Q43831814-234F8F90-13D2-4CB1-9CB9-74182CBDB7DD
P2860
Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Efficacy of venlafaxine for th ...... bo-controlled phase III trial.
@ast
Efficacy of venlafaxine for th ...... bo-controlled phase III trial.
@en
Efficacy of venlafaxine for th ...... bo-controlled phase III trial.
@nl
type
label
Efficacy of venlafaxine for th ...... bo-controlled phase III trial.
@ast
Efficacy of venlafaxine for th ...... bo-controlled phase III trial.
@en
Efficacy of venlafaxine for th ...... bo-controlled phase III trial.
@nl
prefLabel
Efficacy of venlafaxine for th ...... bo-controlled phase III trial.
@ast
Efficacy of venlafaxine for th ...... bo-controlled phase III trial.
@en
Efficacy of venlafaxine for th ...... bo-controlled phase III trial.
@nl
P2093
P2860
P921
P356
P1433
P1476
Efficacy of venlafaxine for th ...... ebo-controlled phase III trial
@en
P2093
F Goldwasser
G Deplanque
J M Gornet
J P Durand
P2860
P304
P356
10.1093/ANNONC/MDR045
P50
P577
2011-03-22T00:00:00Z